S&P 500 Industrials Sector SEC Filings — May 14, 2026

14-05-2026

14-05-2026

Dawson Geophysical Co filed an 8-K on 2026-05-14 under Item 2.02 disclosing results of operations and financial condition, with Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, balance sheet details, period-over-period comparisons, guidance, or other quantitative metrics are mentioned in the provided filing information. This is a multi-item filing focused on financial results announcement.

14-05-2026

14-05-2026

14-05-2026

14-05-2026

14-05-2026

14-05-2026

Apellis Pharmaceuticals, Inc. completed its acquisition by Biogen Inc. via tender offer and merger effective May 14, 2026, with shareholders receiving $41.00 per share in cash plus one non-transferable CVR potentially worth up to $4.00 upon milestone achievements. The company notified Nasdaq of the merger, halted trading, and plans to delist, deregister, and terminate SEC reporting obligations. Holders of the outstanding $93,897,000 principal amount of 3.500% Convertible Senior Notes due 2026 can elect to convert with a make-whole premium (yielding $1,080.77 cash and 26.3411 CVRs per $1,000 principal) until June 29, 2026, or require repurchase at 100% principal plus accrued interest (approx. $1,008.46 per $1,000) on June 30, 2026.

• · Base Conversion Rate: 25.3405 shares of Common Stock per $1,000 principal (standard); 26.3411 with Additional Shares of 1.0006 for Make-Whole Fundamental Change.
• · Make-Whole Fundamental Change Period: May 14, 2026 to June 29, 2026.
• · Fundamental Change Repurchase Date: June 30, 2026; repurchase at 100% principal plus accrued and unpaid interest.
• · Nasdaq trading halted effective before open on May 14, 2026; Form 25 to be filed for delisting.

14-05-2026

On May 14, 2026, Constellation Energy Generation, LLC issued and sold $750,000,000 aggregate principal of 4.550% Senior Notes due 2029, $600,000,000 of 4.800% Senior Notes due 2032, and $850,000,000 of 5.300% Senior Notes due 2036, for total proceeds of approximately $2.2 billion. The Senior Notes were issued under an existing indenture with U.S. Bank Trust Company, National Association as trustee, with proceeds intended to repay short-term borrowings including commercial paper obligations and for general corporate purposes. No performance declines or flat metrics are reported in this debt issuance filing.

• · Underwriting Agreement dated May 12, 2026.
• · Interest on 2029 and 2036 Senior Notes payable June 1 and December 1 each year, starting December 1, 2026; 2032 Notes payable January 15 and July 15, starting July 15, 2026.
• · Maturities: June 1, 2029 (2029 Notes), January 15, 2032 (2032 Notes), June 1, 2036 (2036 Notes).
• · Senior Notes subject to optional redemption.
• · Legal opinions provided by Ballard Spahr LLP (Exhibits 5.1 and 8.1).

14-05-2026

DC Investments Management, LLC filed its quarterly 13F-HR on May 14, 2026, reporting total equity holdings valued at $261,233,675 as of March 31, 2026, across 76 positions. The portfolio is heavily weighted toward the Vanguard FTSE All-World ex-US ETF ($122,427,309), followed by the SPDR S&P MidCap 400 ETF ($18,917,879) and Piedmont Realty Trust Inc. ($4,892,377). No option positions or voting authority deviations were reported.

• · Filing period end date: March 31, 2026
• · All positions held with sole discretionary voting authority (SH DFND 1)
• · No put or call options reported (all 0)

14-05-2026

On May 14, 2026, Strategic Storage Trust VI, Inc. issued a press release announcing it was ranked the top lifecycle REIT over a three-year period according to Robert A. Stanger & Co. The press release is attached as Exhibit 99.1 and furnished under Item 7.01 for Regulation FD purposes.

14-05-2026

14-05-2026

Edesa Biotech reported fiscal Q2 2026 results with progress in its EB06 Phase 2 vitiligo program, including CRO contracting and site outreach, and additional positive Phase 3 data for paridiprubart showing consistent benefits across ARDS patient subgroups. However, total operating expenses surged $2.7 million to $4.3 million YoY due to higher R&D and G&A, driving net loss to $4.2 million ($0.49/share) from $1.6 million ($0.30/share); for the six months, net loss widened to $6.5 million ($0.78/share) from $3.2 million ($0.74/share). Cash and equivalents stood at $10.0 million with $8.2 million working capital as of March 31, 2026, down slightly from September 30, 2025.

• · Plans to participate in Respiratory Innovation Summit (May 15-16, 2026), ATS 2026 (May 15-20, 2026), Dermatology Drug Development Summit (May 19-21, 2026), and BIO International Convention (Jun 22-25, 2026).
• · Site activations and patient recruitment for EB06 vitiligo study expected midyear 2026, subject to regulatory approval.
• · Net cash used in operating activities $4,103,956 for six months ended Mar 31, 2026.

14-05-2026

14-05-2026

14-05-2026

14-05-2026

LanzaTech reported Q1 2026 revenue of $12.0 million, up 26% YoY from $9.5 million, primarily driven by $6.4 million in engineering services (vs $1.8 million prior year), though partially offset by declines in JDA revenue ($0 vs $1.1 million), licensing ($0.6 million vs $1.1 million), contract research ($1.0 million vs $1.4 million), and flat CarbonSmart sales ($4.1 million vs $4.2 million). Net loss narrowed to $14.7 million from $19.2 million and Adjusted EBITDA loss improved to $7.9 million from $30.5 million, supported by a 59% drop in operating expenses to $13.5 million from $33.0 million; cost of revenue rose slightly to $8.3 million from $7.5 million. The company raised $30 million in gross proceeds from private placements ($20 million in January and $10 million in May, with option for additional $20 million), boosting cash to $23.8 million and alleviating going concern doubts, alongside project milestones like India ethanol plant contract and Japan MSW performance.

• · LanzaJet Series A at $650M pre-money valuation; LanzaTech ownership reduced to ~46%.
• · Japan MSW-Ethanol plant achieved ethanol yields exceeding guaranteed performance from unsorted MSW syngas.
• · Going concern substantial doubt alleviated post-capital raises and cost optimizations.

14-05-2026

GEE Group Inc. filed an S-3 shelf registration statement on May 14, 2026, enabling potential offerings of common stock, preferred stock, debt securities, warrants, rights, or units for working capital, capital expenditures, acquisitions, and general corporate purposes. The company operates professional staffing services through subsidiaries like Access Data Consulting, Agile Resources, Paladin Consulting, Scribe Solutions, and SNI Companies, focusing on IT, engineering, accounting, finance, and healthcare verticals, after selling its Industrial Staffing segment in fiscal 2025. On March 10, 2026, it engaged Roth Capital Partners to review unsolicited expressions of interest and evaluate strategic alternatives to maximize shareholder value, though no transaction is assured.

• · Company incorporated in Illinois in 1962, successor to employment offices since 1893.
• · Operates from 4 virtual locations and 14 branch offices near major U.S. cities including Atlanta, Dallas, Denver, and Miami.
• · Six acquisitions completed since 2015, most recent being Hornet Staffing in fiscal 2025.
• · Fiscal year ends September 30.
• · Common stock trades on NYSE American under symbol 'JOB'.
• · No preferred stock outstanding as of May 13, 2026.

14-05-2026

14-05-2026

14-05-2026

14-05-2026

14-05-2026

CSX Corporation announced the immediate separation of Stephen Fortune, Executive Vice President and Chief Digital & Technology Officer, with Steve Watkins assuming his responsibilities reporting to CFO Kevin S. Boone; Fortune is eligible for severance under the CSX Executive Severance Plan. At the May 12, 2026 Annual Meeting, shareholders elected all 12 director nominees (noting significant opposition to John J. Zillmer with 299,018,366 against votes and Linda H. Riefler with 103,201,665 against), ratified Ernst & Young LLP as auditors for 2026, and approved named executive officer compensation on an advisory basis (with 98,932,409 against). The Board authorized a new $5 billion share repurchase program, providing incremental authority atop $989 million remaining as of March 31, 2026.

• · Annual Meeting held on May 12, 2026; 8-K filed May 14, 2026 with earliest event May 12, 2026.
• · Proxy Statement filed March 30, 2026 describing Executive Severance Plan.
• · Share repurchases may use open market, Rule 10b5-1 plans, accelerated repurchases, or block purchases, subject to Board discretion.

14-05-2026

Cabaletta Bio, Inc. reported a widened net loss of $43,515 thousand for the three months ended March 31, 2026, up 21% YoY from $35,943 thousand, primarily due to research and development expenses rising 29% YoY to $37,353 thousand while general and administrative expenses declined 15% to $6,943 thousand. Cash and cash equivalents increased 41% QoQ to $116,635 thousand from $82,982 thousand at December 31, 2025, supported by $50,960 thousand from investment maturities and $29,538 thousand in net proceeds from equity issuances, though operating cash use intensified to $42,561 thousand. Total assets fell to $148,146 thousand from $165,083 thousand, with stockholders' equity decreasing to $103,305 thousand from $112,051 thousand amid the larger accumulated deficit of $560,472 thousand.

• · Weighted-average common shares outstanding increased to 112,025,474 in Q1 2026 from 50,743,101 in Q1 2025, improving net loss per share to $(0.39) from $(0.71).
• · Proceeds from ATM offering: $22,568 thousand; from warrant exercises: $6,938 thousand in Q1 2026.
• · Short-term investments fully matured at $50,617 thousand as of December 31, 2025, contributing to cash increase.

14-05-2026

NIQ reported strong Q1 2026 results exceeding expectations, with total revenue up 11.1% YoY to $1,072.7 million (5.1% OCC growth led by Americas at 9.3% OCC and EMEA at 4.6% OCC), Adjusted EBITDA up 19.1% to $224.8 million (margin expanded 150 bps to 21.0%), and significant improvements in net loss, Adjusted net income, and free cash flow. However, APAC revenue declined 1.0% reported (-3.6% OCC), and Americas Adjusted EBITDA margin was slightly down 10 bps to 28.3%. The company reaffirmed FY2026 guidance of 5.0%-5.3% OCC revenue growth, 23.5%-23.8% Adjusted EBITDA margin, and $235.0M-$250.0M levered free cash flow, while announcing a 2026 Restructuring Program targeting $70-$80 million annual cost savings.

• · Landed 17 seven-figure wins including renewals, upsells, and competitive win-backs.
• · eCommerce revenue growth accelerated to 33%; grew to 209 Full View Measurement clients.
• · Selected by Ulta Beauty as primary beauty insights panel provider.
• · 2026 Restructuring Program expected to incur $65-$75 million pre-tax charges, mostly cash.
• · Cash paid for capital expenditures $59.6 million (5.6% of revenue) in Q1 2026 vs. $62.7 million (6.5%) in Q1 2025.
• · Ongoing integration of AI expected to generate additional $70-$80 million annualized cost savings.

14-05-2026

Hyperion DeFi reported record Q1 2026 GAAP Net Income of $8,840,550 and Non-GAAP Adjusted EBITDA of $19,488,132, with Adjusted Gross Profit up 17% QoQ to $959,568 driven by DeFi Monetization (+140% to $245k) and Yield Enhancement (+165% to $211k), alongside treasury growth to 1.94M Gross HYPE Tokens ($71.0M holdings) at quarter-end and over 2.00M as of May 11. However, Ecosystem Rewards declined 47% QoQ to $150k, Validator Commissions fell 17% to $40k, Staking Yield was up only 2% to $313k (flat), and operating activities used $4.2M net cash. The company raised FY2026 Adjusted Gross Profit guidance by ~20% to $5M-$7M (~5x FY2025 actuals).

• · Net Cash Used in Operating Activities: $4.2M in Q1 2026 (would be $2.7M excluding $1.5M net increase in operating assets)
• · Cash, Cash Equivalents, and USDH: $9.1M end Q1 2026, $16.0M as of May 11, 2026
• · Net Cash Used in Investing Activities for HYPE purchases: $1.5M Q1 2026; additional $2.5M QTD Q2'26 to May 11
• · Net Cash Provided by Financing Activities: $6.6M Q1 2026; additional $1.9M QTD Q2'26 to May 11 from ATM offering; $8.7M from May 7 public offering of 2,777,778 shares
• · Earnings conference call: May 14, 2026 at 8:00 a.m. Eastern Time

14-05-2026

Western New England Bancorp, Inc. (WNEB) presented at its 2026 Annual Shareholders’ Meeting, highlighting 2025 quarterly financials with net income improving to $5,209 thousand in 4Q2025 (EPS $0.26, ROA 0.75%) from $2,303 thousand in 1Q2025 (EPS $0.11, ROA 0.35%), and Q1 2026 results showing EPS of $0.24 (up YoY from $0.11 but down QoQ from $0.26) with ROA at 0.71% (up YoY but down QoQ from 0.75%). Balance sheet grew with total loans at $2.3 billion as of March 31, 2026 (up from $2.1 billion YoY) and deposits at approximately $2.4 billion, while NIM improved to 2.97% tax-equivalent basis in Q1 2026 (up QoQ from 2.91%). However, ROE declined QoQ to 7.77% from 8.40%, and certain quarters showed provisions for credit losses.

• · Shareholder proposals include election of four directors (Laura J. Benoit, Donna J. Damon, Lisa G. McMahon, Steven G. Richter) for three-year terms, advisory vote on executive compensation, and ratification of Wolf & Company, P.C. as independent auditor for FY 2026.
• · Strong asset quality in 2025: Allowance for Credit Losses at 0.93% of total loans, coverage of nonaccrual loans at 393%, nonaccrual loans 0.32% of total loans.
• · Loan-to-asset ratio reached 80% in 2025, up from 73% historically; borrowings-to-total assets at 4%.

14-05-2026

Mizuho Bank, Ltd. filed a 13F-HR disclosing $369,481,064 in U.S. equity holdings as of March 31, 2026. The portfolio consists of four positions: SPDR S&P 500 ETF Trust ($102,753,720, 158,000 shares), Select Sector SPDR Energy ($200,932,800, 3,280,000 shares), Invesco DB Multi-Sector Comm Agriculture Fund ($35,516,000, 1,300,000 shares), and CME Group Inc. ($30,278,544, 102,518 shares). No share changes were reported for these holdings.

• · Filing period end date: March 31, 2026
• · Filed on: May 14, 2026
• · Business address: 1-5-5, Otemachi, Chiyoda-ku, Tokyo 100-8176, Japan

14-05-2026

Forgent Power Solutions reported fiscal Q3 2026 revenues of $379 million, up 103% YoY from $186 million, with record bookings of $867 million (up 308% YoY) and backlog of $1.98 billion (up 157% YoY and 33% QoQ). Net income increased 190% YoY to $24 million (6.5% margin, up ~650 bps QoQ), Adjusted EBITDA rose 96% to $85 million (22.4% margin, up ~200 bps QoQ), and cash flow from operations improved to $29 million. The company raised FY2026 guidance to $1,350-$1,390 million revenue (82% YoY midpoint), $310-$320 million Adjusted EBITDA (86% YoY), and $197-$207 million Adjusted Net Income (128% YoY), though margins were modestly impacted by under-absorbed labor/overhead costs and startup expenses at new facilities (1.8% of revenues vs. 2.0% prior quarter).

• · Book-to-bill ratio of 2.3x in Q3 FY2026 vs. 1.1x in prior year quarter
• · Q4 FY2026 revenue guidance: $392-$432 million
• · Q4 FY2026 Adjusted EBITDA guidance: $100-$110 million
• · Expected capacity post-expansion to support up to $5 billion annual revenues
• · Conference call on May 14, 2026 at 11:00 a.m. Eastern Time

14-05-2026

Lord, Abbett & Co. LLC filed its 13F-HR on May 14, 2026, reporting equity and other securities holdings as of March 31, 2026, across 557 investment titles with a total market value of $30,630,739. Notable positions include Alphabet Inc. Cap Stk Com ($885,734), Broadcom Inc. ($514,820), Apple Inc. ($502,806), Exxon Mobil Corp. ($414,429), and Eli Lilly & Co. ($387,815). The filing provides a standard quarterly snapshot with no period-over-period comparisons available.

• · Report period end date: 2026-03-31
• · Filed as of date: 2026-05-14
• · SEC file number: 028-00413
• · Business address: 30 Hudson Street, Jersey City, NJ 07302
• · State of incorporation: DE

14-05-2026

Intelligent Bio Solutions Inc. reported fiscal Q3 2026 revenue of $1,060,802, up 46% YoY from $728,867, driven by cartridge sales growth of 59% to $703,538 (66% of revenue) and other sales up 80% to $217,857, though reader sales declined 16% to $139,407. Nine-month revenue reached $3,069,373, up 39% YoY from $2,208,648, with gross margins expanding to 50.5% in Q3 (from 46.8%) and 49.3% for the nine months (up 800 basis points). Despite revenue gains, Q3 net loss widened to $2,869,640 from $2,550,674, reflecting higher operating expenses.

• · Cash and cash equivalents increased to $6,862,204 at March 31, 2026 from $740,371 at December 31, 2025.
• · Total assets $14,862,792 at March 31, 2026, up from $8,249,786 at June 30, 2025.
• · Q3 operating loss $2,947,101, wider than $2,560,329 YoY.
• · Nine-month operating expenses $10,584,443, up from $8,917,114 YoY.

14-05-2026

Mercury General Corporation held its 2026 Annual Meeting of Shareholders on May 13, 2026, electing all nine director nominees with votes for ranging from 39,115,597 to 40,720,444 shares, though Martha E. Marcon faced the highest withheld votes at 1,810,103. Shareholders approved, on an advisory basis, named executive officer compensation (40,328,913 for, 568,701 against) and ratified KPMG LLP as independent auditor for the fiscal year ending December 31, 2026 (42,985,321 for, 511,025 against). Broker non-votes were consistent at 2,584,625 across director elections and compensation vote.

• · Meeting held on May 13, 2026; filing dated May 14, 2026
• · Auditor ratification for fiscal year ending December 31, 2026
• · Commission File No. 001-12257; I.R.S. Employer Identification No. 95-2211612

14-05-2026

Gesher Acquisition Corp. II reported net income of $891,601 for the three months ended March 31, 2026, a significant YoY increase of 2,922% from $29,499, driven by higher interest income of $1,304,269 on Trust Account securities (up 1,047% YoY). However, general and administrative expenses rose sharply 390% YoY to $412,668, leading to a larger operating loss, while cash decreased 46% QoQ to $589,283 amid ongoing cash burn from operations. Marketable securities in the Trust Account grew slightly 0.9% QoQ to $150,028,760, but shareholders' deficit widened 9.7% QoQ to $(4,657,291).

• · Deferred underwriting fee remains at $5,031,250.
• · Basic and diluted net income per share for both Class A and Class B Ordinary Shares was $0.04 for Q1 2026, up from $0.00 in Q1 2025.
• · Net cash used in operating activities was $503,926 for Q1 2026, compared to $231,741 in Q1 2025.

14-05-2026

FingerMotion, Inc., a Delaware corporation with operations in Singapore, entered into a Securities Purchase Agreement dated May 13, 2026, with certain buyers to issue and sell Notes in a private placement pursuant to Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. The Closing is scheduled for no later than the second Business Day after execution, subject to satisfaction of conditions. The agreement includes representations confirming no material adverse effects since the latest financial statements, compliance with laws, valid intellectual property, adequate insurance, and no undisclosed liabilities or litigation with material impact.

• · Commission payable to Weild & Co for the transaction.
• · No brokerage or finder's fees payable to others.
• · Company address: 111 Somerset Road, Level 3, Singapore.

14-05-2026

Silo Pharma, Inc. reported a net loss of $1,647,117 for the three months ended March 31, 2026, widening approximately 60% YoY from $1,031,437, primarily due to sharply higher research and development expenses of $1,013,265 (up 70% YoY) and a gross loss of $2,662 versus a $16,566 profit in the prior year, despite flat license fee revenue of $18,026. Total assets declined to $7,018,132 from $7,605,100 at December 31, 2025, with cash and equivalents at $3,902,514 (down QoQ), though net cash used in operating activities improved to $822,623 from $1,640,300 YoY. Stockholders' equity decreased to $5,681,836 amid increased shares outstanding to 16,266,593.

• · Crypto assets at fair value decreased to $173,462 from $221,817 QoQ.
• · Gross profit turned to a loss of $2,662 from $16,566 YoY due to higher cost of revenues $20,688 vs $1,460.
• · Common stock issued: 848,320 shares for future services ($250,000) and 2,100,000 shares for acquired technology ($714,000).
• · Intangible assets net $214,438 (license with 20-year life).
• · Net cash used in investing activities $23,563 in Q1 2026 vs provided $871,381 in Q1 2025.

14-05-2026

Launchpad Cadenza Acquisition Corp I reported net income of $1,726,095 for the three months ended March 31, 2026, driven by $2,033,672 in interest income primarily from the Trust Account, which grew to $232,265,476 from $230,231,978 at December 31, 2025. However, the company recorded an operating loss of $307,577 and cash decreased by $362,823 to $907,573 amid net cash used in operations of $344,060. Shareholders’ deficit widened slightly to $(9,880,345) due to accretion of $2,033,498 offsetting net income.

• · Due from Sponsor remained at $25,000 as of March 31, 2026.
• · Total liabilities increased to $11,124,152 from $11,058,234.
• · Net cash used in operating activities: $344,060; net cash used in financing activities: $18,763.

14-05-2026

Applied Energetics reported zero revenue for Q1 2026, down 100% YoY from $209,753, leading to an operating loss of $3,830,108 (up 23% YoY from $3,105,680) driven by higher G&A expenses ($3,282,788 vs $2,609,688). Net loss attributable to common stockholders widened to $3,816,224 ($0.02 per share) from $3,114,167 ($0.01 per share), while cash and equivalents fell 37% QoQ to $4,064,093 from $6,436,082 amid $2,296,313 cash used in operations. Total assets declined to $6,629,274 from $9,064,658 at year-end, with stockholders' equity dropping 32% to $5,115,996.

• · Net cash used in operating activities: $2,296,313 in Q1 2026 vs $1,731,610 in Q1 2025.
• · Stock-based compensation expense: $1,348,232 in Q1 2026 vs $991,793 in Q1 2025.
• · G&A expenses: $3,282,788 in Q1 2026, down from prior quarter but up YoY.
• · Property and equipment net: $1,222,287 as of March 31, 2026 (down from $1,267,037 Dec 31, 2025).

14-05-2026

Oaktree Gardens OLP, LLC's total investment income for the three months ended March 31, 2026 rose 17% YoY to $24,092, driven by higher interest income from non-control/non-affiliate investments (+18% to $22,767), with net investment income up 18% YoY to $13,531. However, net unrealized depreciation widened to $5,985 from $1,429 YoY, leading to a 20% YoY decline in net increase in net assets from operations to $8,054 and earnings per common unit falling to $0.36 from $0.46; over six months, operations were nearly flat at $21,813 versus $21,655 YoY. Balance sheet showed investments at fair value increasing to $934,496 from $912,864 at September 30, 2025 (QoQ +2.4%), but total assets dipped to $971,554 from $989,537 (-1.8%) and net assets to $450,472 from $452,469 (-0.4%), with NAV per unit at $20.10 versus $20.41.

• · Credit facility borrowings: net repayment of $17,500 QoQ to $511,000 from $528,500.
• · Distributions to unitholders for six months ended March 31, 2026: $28,700 versus $22,000 YoY.
• · Operating cash flow for six months: $30,761 provided versus $189,190 used YoY.
• · Common units issued during six months: 4,890 versus 89,600 YoY.

14-05-2026

Gemsstock Ltd. filed its 13F-HR report on May 14, 2026, disclosing $948797124 total portfolio value as of March 31, 2026, across 28 equity positions primarily in energy, gold/mining, and technology sectors. Top holdings by value include Equinox Gold Corp ($119759238), Gulfport Energy Corp ($107523471), and Amazon.com Inc ($60252511), with all positions reported as solely owned shares and no other investment types indicated. No period-over-period changes are detailed in this filing.

• · Filing CIK: 0001724140
• · Filer address: 4th Floor, 18 Henrietta Street, London X0 WC2E 8QH
• · All 28 positions reported as SH SOLE (sole voting and disposition power) with no puts, calls, or other manager categories
• · Business phone: 00442037405132

14-05-2026

Rhenman & Partners Asset Management AB filed its 13F-HR on May 14, 2026, disclosing equity holdings as of March 31, 2026, totaling $810,489,964 across 86 positions, primarily in healthcare, biotechnology, and pharmaceuticals sectors. Top holdings include Boston Scientific Corp ($39,218,750 for 625,000 shares), Regeneron Pharmaceuticals ($37,163,984 for 48,100 shares), Eli Lilly & Co ($31,010,046 for 33,715 shares), and CVS Health Corp ($24,167,430 for 336,500 shares). No period-over-period changes are provided in this filing.

• · All positions reported as sole investment discretion.
• · Filing CIK: 0001599882; SEC File Number: 028-15944.
• · Business address: Strandvagen 5A, Stockholm V7 11451, Sweden.

14-05-2026

Golden Star Resource Corp. reported a net loss of $14,135 for the three months ended March 31, 2026, up 3.4% from $13,669 in the prior year period, driven by higher professional fees, transfer fees, and flat office expenses. For the nine months ended March 31, 2026, the net loss improved to $47,025 from $51,523, a 8.7% reduction, primarily due to lower office expenses. However, total liabilities rose to $942,737 from $891,112, with increases in accounts payable and accrued liabilities ($172,440 vs. $154,395) and due to related parties ($486,239 vs. $452,659), while total assets remained minimal at $7,545.

• · Cash balance unchanged at $45 as of March 31, 2026 and June 30, 2025.
• · Loan payable steady at $284,058.
• · Accumulated deficit increased to $(1,042,253) from $(995,228).
• · $458,239 of due to related parties as of March 31, 2026 payable to a principal shareholder’s company for operating expenses.

14-05-2026

Polymer Capital Management (HK) LTD filed a 13F-HR on May 14, 2026, disclosing total holdings of $1,157,339,604 across 154 positions as of March 31, 2026. The portfolio consists primarily of equity positions and some options in technology, semiconductors, and growth stocks including Advanced Micro Devices, Airbnb, Akamai Technologies, Alibaba Group, Alphabet, Amazon.com, and numerous ETFs like iShares and SPDR sector funds. No period-over-period changes are provided in the filing.

• · Report period end date: March 31, 2026
• · Filing as of date: May 14, 2026
• · Business address: No. 2401-06, 24/F, Three Pacific Place, 1 Queen's Road East, Hong Kong
• · SEC file number: 028-23815

14-05-2026

Reliance Global Group, Inc. filed Articles of Amendment to its Articles of Incorporation, implementing a 1-for-40 reverse stock split effective upon filing with the Florida Division of Corporations, reducing authorized Common Stock from 2,000,000,000 to 50,000,000 shares (97.5% reduction) and setting total authorized shares at 800,000,000 including 750,000,000 Preferred Stock shares. The amendment was adopted by the Board of Directors via unanimous written consent on May 7, 2026, without shareholder approval, with Nasdaq trading effective expected on May 18, 2026. No fractional shares will be issued; holders receive one whole share rounded up.

• · Articles adopted pursuant to Sections 607.1006, 607.10025, and 607.10025(7) of the Florida Business Corporation Act.
• · Signed on May 12, 2026.
• · Transfer agent authorized to round up fractional shares to one whole share.

14-05-2026

First International Bank of Israel Ltd., a subsidiary of F.I.B.I. Holdings Ltd., filed its 13F-HR on May 14, 2026, disclosing 59 U.S.-listed equity holdings as of March 31, 2026, primarily consisting of ETFs and select large-cap stocks. Significant positions include $38.2M in FIRST TR EXCHNG TRADED FD VI FT VEST US EQT (CUSIP 33740U679) and $28.9M in FIRST TR EXCHNG TRADED FD VI FT VEST US (CUSIP 33740F631), alongside stocks like Amazon.com Inc. ($5.6M) and Apple Inc. ($2.3M). The Bank manages these directly, through subsidiaries, or via HaBeinleumi Unique Portfolio Management Ltd. for clients, disclaiming any control group with its parent.

• · Securities reported are beneficially owned by the Bank, subsidiaries, or purchased by Unique on behalf of clients with investment discretion.
• · Filer and parent F.I.B.I. Holdings Ltd. operate under independent management with separate voting and investment decisions.
• · Includes only dual-listed securities on U.S. and Tel Aviv exchanges that were purchased in the U.S., per SEC guidance.
• · Business address: 42 Rothschild Blvd, Tel Aviv, L3 6688310, Israel

14-05-2026

Raphael Pharmaceutical Inc. reported a reduced net loss of $229 thousand for Q1 2026 (three months ended March 31, 2026), improving 47% YoY from $429 thousand, with R&D expenses down 49% to $37 thousand and G&A down 47% to $186 thousand. However, cash and equivalents sharply declined to $1 thousand QoQ from $45 thousand, leaving total assets at $3 thousand amid a 12% rise in current liabilities to $1,665 thousand driven by related-party payables. Stockholders' equity deficit worsened to $(1,662) thousand from $(1,433) thousand, signaling ongoing liquidity pressures.

• · Net cash used in operating activities improved to $44 thousand in Q1 2026 from $209 thousand in Q1 2025.
• · Weighted average shares used in EPS: 20,176,418 in Q1 2026 vs 19,626,418 in Q1 2025.
• · Basic and diluted net loss per share: $0.01 in Q1 2026 vs $0.02 in Q1 2025.
• · Entity is a small business, non-accelerated filer, incorporated in NV, operations in Tel Aviv, Israel.

14-05-2026

Campion Asset Management, based in Fairfax, VA, filed its 13F-HR disclosing 82 equity positions with a total market value of $147,443,985 as of March 31, 2026. Top holdings include iShares Core S&P Mid-Cap ETF ($15,741,596), iShares Core S&P 500 ETF ($15,178,660), Lockheed Martin Corp ($10,509,133), and Vanguard Tax-Managed Funds FTSE Developed Markets ETF ($9,976,154). Other significant positions feature Apple Inc ($4,370,234), Exxon Mobil Corp ($2,619,880), and Eli Lilly & Co ($2,512,812).

• · All 82 positions held with sole voting and investment discretion.
• · Filed on May 14, 2026, for period ending March 31, 2026.
• · Business address: 11325 Random Hills Road, Suite 360, Fairfax, VA 22030.